GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ABBV-399 | ABBV399 | ABT-700-vcMMAE | Emrelis® | Teliso-V | telisotuzumab vedotin-tllv
telisotuzumab vedotin is an approved drug
Compound class:
Antibody
Comment: Telisotuzumab vedotin (ABBV-399; ABT-700) is an antibody-drug conjugate (ADC). It is a conjugate of the anti-hepatocyte growth factor receptor (HGFR; c-Met) antibody ABT-700 and the cytotoxic microtubule inhibitor MMAE (or vedotin) [3]. It was designed for anti-tumour activity in malignancies with MET amplification and/or c-Met overexpression, and that express constitutive c-Met signalling or ligand-dependent activation of c-Met.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. US FDA (2025) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10365 | telisotuzumab vedotin |
| Synonyms |
| ABBV-399 | ABBV399 | ABT-700-vcMMAE | Emrelis® | Teliso-V | telisotuzumab vedotin-tllv |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 653 |
| Other databases | |
| GtoPdb PubChem SID | 513757593 |
| Search PubMed clinical trials | telisotuzumab vedotin |
| Search PubMed titles | telisotuzumab vedotin |
| Search PubMed titles/abstracts | telisotuzumab vedotin |
